Niel (Belgium), 25 September 2017 — eTheRNA Immunotherapies, a clinical-stage company developing mRNA-based cancer immunotherapies from its unique TriMix platform, announces it has been awarded a €1 million industrial R&D Projects Grant by Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used by eTheRNA to further develop and optimize its state-of-the-art production process for generating the mRNA components of its TriMix platform, and for clinical trials of innovative and rationally designed mRNA cancer immunotherapies derived from this platform. The improved production process will enable the Company to further reduce its production time and cost of goods and generate more revenues from the production of GMP-grade mRNA for third parties.
The Company’s unique TriMix platform combines three mRNAs encoding proteins that act highly synergistically to activate dendritic cells (DCs), a type of dedicated immune cells also known as antigen presenting cells (APC), to promote enhanced T-cell immunity. In combination with mRNA coding for tumor-specific antigens, TriMix products can also promote an antigen-directed cytotoxic T-cell response.
Niel (Belgium), 21 September 2017 — eTheRNA immunotherapies, a clinical-stage company developing mRNA-based cancer immunotherapies from its unique TriMix platform, announces that its CEO Dirk Reyn is to present an overview of the company, its novel technologies and development pipeline at the Sachs 17th Biotech in Europe Forum for Global Partnering and Investment.
The presentation will take place on 27 September at 12:15pm in Presentation Track C, which takes place at the Congress Center, Basel, Switzerland.
TriMix-MEL (ECI-006), a rationally designed mRNA immunotherapy based on the unique TriMix platform, starts Phase Ib trial in adjuvant melanoma patients
Niel (Belgium), 30 June 2017 – eTheRNA immunotherapies, a clinical-stage company developing mRNA based cancer immunotherapies from its unique TriMix platform, announces the start of the first Phase Ib oncology clinical study evaluating its novel candidate TriMix-MEL (ECI-006) in metastatic melanoma patients showing no evidence of disease after surgical removal of their tumor, but at risk for disease recurrence.
Exploring synergies between PCI and TriMix technologies to further enhance the effect of novel oncologic therapies
Oslo (Norway) and Niel (Belgium), 8 December 2016 — PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and eTheRNA immunotherapies NV, a VUB spin-off company backed by strong life science investors to continue the development of mRNA-based immunotherapies, today announced that they are initiating a preclinical research collaboration.
More Articles ...
- eTheRNA to appoint Dr. Russell G. Greig as Chairman of the Board
- eTheRNA strengthens management team with the appointment of Alain Deloof as head of the mRNA production lab
- Tijd 50 - De Belgen die uw leven zullen redden
- eTheRNA strengthens management team with appointment of Dr. Karl-Josef Kallen as Chief Medical Officer
- Het beste wapen tegen kanker zit misschien in onszelf